EpimAb
易慕峰
elsewhere's corpus does not cover EpimAb directly. The only material that names the company appears in background references and investor relation tags, which show it as a cell-therapy company that has drawn backing from Gaorong Ventures, LYFE Capital, and ZhenFund—including a roughly ¥200 million Pre-IPO round led by Gaorong and LYFE in early 2026 —but these snippets are not *about* EpimAb itself and do not support a substantive profile of what the company does, its pipeline, or its history.
AI-generated — may contain errors, please verify.
Coverage
Rongbao | Karl Dynamics, Aerofugia, StarsComm, and ImmuPeak Kick Off the Year with Major Funding Rounds
Leading the industry into a new era.
Beyond the Set Trajectory | Z News
We look back at the "highlight moments" of the past month and invite you to witness the growth of our portfolio companies and what's new at ZhenFund.
Venture Where No One Has Gone Before | Z News
July is drawing to a close, and we invite you to join us in witnessing the growth of our portfolio companies and what's new at ZhenFund.
